Literature DB >> 21556881

Immunologic similarities between selected autoimmune diseases and peanut allergy: possible new therapeutic approaches.

Michael A Martucci1, Stephen C Dreskin.   

Abstract

Food allergies are an important medical problem in Westernized countries. Allergy to peanuts is a dramatic example of a food allergy that tends to be particularly severe and long-lived. This article examines food allergy-specifically peanut allergy-from the perspective that tolerance to foods is a normal state, just as tolerance to self-proteins is a normal state. From this vantage point, loss of tolerance to foods in food-allergic individuals can be viewed as parallel to the loss of tolerance to self-proteins in those with autoimmune diseases. Although our knowledge base is far from satisfactory, there are important similarities in the immunologic abnormalities that are characteristic of both peanut allergy and several autoimmune diseases. Delineation of these similarities may open the door to new therapeutic approaches for the treatment of severe food allergies.

Entities:  

Mesh:

Year:  2011        PMID: 21556881     DOI: 10.1007/s11882-011-0201-z

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  49 in total

1.  Cat and dust mite allergen levels, specific IgG and IgG4, and respiratory symptoms in adults.

Authors:  Deborah Jarvis; Jan-Paul Zock; Joachim Heinrich; Cecilie Svanes; Giuseppe Verlato; Mario Olivieri; Simona Villani; Michela Ponzio; Benedicte Leynaert; Jordi Sunyer; Anna Dahlman-Hoglund; Susan Chinn; Christina Luczynska; Dan Norbäck; Peter Burney
Journal:  J Allergy Clin Immunol       Date:  2007-01-30       Impact factor: 10.793

Review 2.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 3.  Peanut allergens.

Authors:  W Burks; H A Sampson; G A Bannon
Journal:  Allergy       Date:  1998-08       Impact factor: 13.146

4.  Allergy to peanut.

Authors:  J O Hourihane; J O Warner
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.

Authors:  Francisco Javier Peñalver; Alberto Alvarez-Larrán; Jose Luis Díez-Martin; Laura Gallur; Isidro Jarque; Dolores Caballero; Joaquín Díaz-Mediavilla; Rosalía Bustelos; María Jesús Fernández-Aceñero; José Rafael Cabrera
Journal:  Ann Hematol       Date:  2010-06-05       Impact factor: 3.673

6.  Human subjects without peanut allergy demonstrate T cell-dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression.

Authors:  Tina B Thottingal; Bill P Stefura; F Estelle R Simons; Gary A Bannon; Wesley Burks; Kent T HayGlass
Journal:  J Allergy Clin Immunol       Date:  2006-08-24       Impact factor: 10.793

7.  Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

Authors:  P P Tak; R M Thurlings; C Rossier; I Nestorov; A Dimic; V Mircetic; M Rischmueller; E Nasonov; E Shmidt; P Emery; A Munafo
Journal:  Arthritis Rheum       Date:  2008-01

8.  Safety of a peanut oral immunotherapy protocol in children with peanut allergy.

Authors:  Alison M Hofmann; Amy M Scurlock; Stacie M Jones; Kricia P Palmer; Yuliya Lokhnygina; Pamela H Steele; Janet Kamilaris; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-05-27       Impact factor: 10.793

Review 9.  Food allergy.

Authors:  Scott H Sicherer; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2009-12-29       Impact factor: 10.793

Review 10.  Allergy and the gastrointestinal system.

Authors:  G Vighi; F Marcucci; L Sensi; G Di Cara; F Frati
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.